787 related articles for article (PubMed ID: 25617253)
21. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
22. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Kramer M; Simpson G; Maciulis V; Kushner S; Vijapurkar U; Lim P; Eerdekens M
J Clin Psychopharmacol; 2007 Feb; 27(1):6-14. PubMed ID: 17224706
[TBL] [Abstract][Full Text] [Related]
23. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.
Singh J; Robb A; Vijapurkar U; Nuamah I; Hough D
Biol Psychiatry; 2011 Dec; 70(12):1179-87. PubMed ID: 21831359
[TBL] [Abstract][Full Text] [Related]
24. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.
Cameron C; Zummo J; Desai DN; Drake C; Hutton B; Kotb A; Weiden PJ
Value Health; 2017; 20(7):876-885. PubMed ID: 28712616
[TBL] [Abstract][Full Text] [Related]
25. Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.
Gattaz WF; Campos JA; Lacerda AL; Henna E; Ruschel SI; Bressan RA; de Oliveira IR; Rocha FL; Grabowski HM; Sacomani E; Louzã MR; Quevedo J; Elkis H; Zorzetto Filho D; Périco Cde A; Lawson FL; Appolinário JC
Curr Med Res Opin; 2014 Apr; 30(4):695-709. PubMed ID: 24289141
[TBL] [Abstract][Full Text] [Related]
26. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
[TBL] [Abstract][Full Text] [Related]
27. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
Citrome L; Du Y; Risinger R; Stankovic S; Claxton A; Zummo J; Bose A; Silverman BL; Ehrich EW
Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202
[TBL] [Abstract][Full Text] [Related]
28. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
[TBL] [Abstract][Full Text] [Related]
30. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.
Correll CU; Kohegyi E; Zhao C; Baker RA; McQuade R; Salzman PM; Sanchez R; Nyilas M; Carson W
J Am Acad Child Adolesc Psychiatry; 2017 Sep; 56(9):784-792. PubMed ID: 28838583
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
[TBL] [Abstract][Full Text] [Related]
32. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
[TBL] [Abstract][Full Text] [Related]
33. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776
[TBL] [Abstract][Full Text] [Related]
34. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.
Canuso CM; Bossie CA; Turkoz I; Alphs L
Schizophr Res; 2009 Aug; 113(1):56-64. PubMed ID: 19560322
[TBL] [Abstract][Full Text] [Related]
35. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
[TBL] [Abstract][Full Text] [Related]
37. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
Turkoz I; Bossie CA; Lindenmayer JP; Schooler N; Canuso CM
BMC Psychiatry; 2011 Feb; 11():21. PubMed ID: 21299844
[TBL] [Abstract][Full Text] [Related]
38. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.
Vieta E; Nuamah IF; Lim P; Yuen EC; Palumbo JM; Hough DW; Berwaerts J
Bipolar Disord; 2010 May; 12(3):230-43. PubMed ID: 20565430
[TBL] [Abstract][Full Text] [Related]
39. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]